Tolmar Expands Operations with New Laboratory at Rosalind Franklin University

Rosalind Franklin University of Medicine and Science has officially welcomed the new Northern Illinois Laboratory for Tolmar, Inc., a specialty pharmaceutical company, to its Innovation and Research Park (IRP). This facility aims to enhance Tolmar’s capabilities in the development and commercialization of pharmaceutical products while enriching the university’s ecosystem of industry innovation.

Founded in 2007, Tolmar is globally recognized for its proficiency in advanced long-acting injectable drug delivery. The company specializes in developing and manufacturing long-acting injectables targeting areas such as urology, oncology, and endocrinology. Among its notable products is a treatment for advanced prostate cancer, which is marketed in 89 countries worldwide.

The new laboratory at Rosalind Franklin will expand Tolmar’s existing operations, complementing its research team based in Colorado. This strategic move not only enhances Tolmar’s regional footprint but also solidifies its presence in Illinois, where the company has executive offices and sales personnel located in Buffalo Grove.

Dr. Dave Loffredo, Vice President of Innovation at Tolmar, expressed enthusiasm about the expansion. “Tolmar is excited to expand our development capability, now covering both Colorado and Illinois,” he stated. “After an exhaustive search, we found a great home at Rosalind Franklin’s IRP. Tolmar scientists are eager to be a part of this dynamic research environment and hope to grow our presence at IRP.”

Dr. Stace Porter, Senior Vice President of Development Operations for Tolmar, highlighted the advantages of the new facility. “At Rosalind Franklin University’s Innovation and Research Park, Tolmar gains world-class research space and the chance to collaborate with leading scientists and advanced research cores,” he noted. The lab’s location within Lake County is a significant asset, given the area’s robust network of global life science companies.

Rosalind Franklin’s state-of-the-art IRP spans 100,000 square feet and houses six research centers, including the Center for Cancer Cell Biology, Immunology, and Infection. Dr. Joseph DiMario, Executive Vice President for Research at RFU, welcomed Tolmar to the university’s growing list of partners. “We look forward to collaborations that can help accelerate new product development,” he remarked. “The IRP provides an environment that fosters the kind of intellectual biomedical ‘collisions’ that drive meaningful innovation.”

As an integrated specialty pharmaceutical company, Tolmar focuses on developing, manufacturing, and commercializing products across various therapeutic areas. Its operations are not only based in Colorado but also include its commercial headquarters in Illinois.

Rosalind Franklin University, named after the pioneering scientist whose work was crucial to understanding DNA structure, is recognized for its research in fields such as neuroscience, inherited disorders, diabetes, and obesity. This collaboration between Tolmar and RFU is poised to foster significant advancements in pharmaceutical research and product development, benefiting both organizations and the broader healthcare community.

For further information about Tolmar, visit their website at www.tolmar.com. To learn more about Rosalind Franklin University, visit rosalindfranklin.edu.